In patients with advanced non-small-cell lung cancer (NSCLC) with EGFR oncogene addiction, osimertinib is an irreversible, third-generation EGFR tyrosine kinase inhibitor that is extremely selective for EGFR-activating mutations as well as the EGFR T790M mutation [64]. Here, EGFR is linked to non-small cell lung carcinoma.